article thumbnail

Inside The Altascientist Issue 33: CNS Drug Development – Integrated Solutions Lessen Complexity

Alta Sciences

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD by 2028. billion USD in 2023 to $166.53 Image thumbnail-qh33.jpg

article thumbnail

Investment Trends in Pharmaceutical Research

DrugBank

This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The Investment Landscape Despite these challenges, the potential rewards for successful drug development are substantial. trillion by 2028. trillion dollars, and it is forecasted to exceed 1.4

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDIC Releases Latest Information Regarding the Deposit Insurance Restoration Plan

Perficient: Drug Development

percent by the statutory deadline of September 30, 2028. percent by September 30, 2028. percent by the statutory deadline of September 30, 2028. This action became necessary due to extraordinary deposit growth during the first half of 2020, causing the DIF’s reserve ratio to dip below 1.35

article thumbnail

Perficient Mentioned in Two Forrester Reports on Tech-Enabled Clinician Experiences

Perficient: Drug Development

According to Forrester, “Investment in hospital equipment will grow from $36 billion in 2018 to $262 billion in 2028. And that’s easy to understand due to the plethora of available options and new solutions entering the market each day. Yet, HCPs often purchase technology on a team-by-team basis.”

Nurses 98
article thumbnail

Disrupting the CRO Model: Altasciences Participates in Documentary Series for 2024 Global Health Summit

Alta Sciences

The mini documentary explores transformation in the slow-to-change drug development industry. Leaders from Altasciences dive into the obstacles and inefficiencies of the traditional outsourcing relationship between CROs and drug sponsors, and how Altasciences has broken from tradition to address these challenges.

article thumbnail

Models of Life

Codon

2028 Over the next year, the scientific community ferociously interrogated the model. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. Unlike what many predicted, the rise of computation as a dominant force in drug development did not kill “Big Pharma.”

article thumbnail

Nine Key Takeaways from Dreamforce 2023

Perficient: Drug Development

jobs by 2028. This solidifies that Salesforce is leading the charge in AI, and Perficient is leaning into the partnership to bring innovative solutions to our clients. We learned about new Salesforce capabilities and technologies, heard new product announcements, and connected with peers and clients from across industries.